Hyderabad: City-based pharma giants Dr Reddy’s Laboratories (DRL) and   Pharma have initiated drug recalls from the US market. While DRL has recalled Olanzapine tablets, used to treat symptoms of psychotic conditions such as schizophrenia and bipolar disorder, Aurobindo has recalled Pantoprazole Sodium for injection that is used in the treatment of gastroesophageal reflux disease. According to information available on the USFDA website, DRL has voluntarily recalled 5,904 bottles of Olanzapine tablets (USP, 2.5 mg, packaged in a 30-count bottles) manufactured at its Bachupally unit. The recall was initiated on October 13, 2016. Citing the reason for the recall, it said, “Failed impurities/degradation specifications: due to out-of-specification result for the related substance compound C (Impurity 6 - N-Oxide at the 18 month stability station)”. The recall falls under ‘Class III’, which according to the USFDA is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences. Aurobindo, on the other hand, has voluntarily recalled 29,800 vials of Pantoprazole Sodium for injection, (single dose 40mg vial) from the US market. The recall was initiated on December 16, 2016., Aurobindo said, “Discoloration: Some vials were found to contain powder with a yellowish-brownish appearance.” tnn
